#site agnostic

Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.

The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.

More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.

Targeted therapy demonstrated high response rates for thyroid tumors with RET mutations or fusions.

The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.

A retrospective analysis showed that 29% of people with previously treated tumors responded to treatment.

Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.

TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.

New site-agnostic therapies highlight the importance of genetic testing.

Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.

FDA approves Rozlytrek for cancers with certain gene mutations

Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.

New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.